| Ytd | 67.76% | |
| 1y | 62.03% |
| Open | 47.25 | Prev Close | 47.41 | Low | 46.46 | High | 47.55 | Mkt Cap | 7.87B |
| Vol | 534.03K | Avg Vol | 1.98M | EPS | 0.38 | P/E | 123.53 | Forward P/E | 25.93 |
| Beta | 0.34 | Short Ratio | 8.72 | Inst. Own | 108.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-28 | 50-d Avg | 50.72 | 200-d Avg | 37.31 | 1yr Est | 56.00 |
ALKS News
Alkermes (NASDAQ: ALKS - Get Free Report) and C4 Therapeutics (NASDAQ: CCCC - Get Free Report) are b
The executive sold 7,576 shares. The transaction resulted in a 7% reduction in the insider's direct
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Shares of Alkermes plc (NASDAQ: ALKS - Get Free Report) passed above its 200-day moving average duri
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from th
Bank of America Corp DE decreased its stake in shares of Alkermes plc (NASDAQ: ALKS) by 9.2% in the
Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel
Glenmede Trust Co. NA trimmed its position in shares of Alkermes plc (NASDAQ: ALKS) by 8.4% during t
JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the pric
Baird analyst Joel Beatty maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price
Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript
ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz add
Piper Sandler analyst David Amsellem reiterates Alkermes (NASDAQ:ALKS) with a Overweight and rais
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the q
Alkermes NASDAQ: ALKS reported second-quarter 2026 revenue of $496 million, supported by growth acro
Alkermes (ALKS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate
Alkermes (NASDAQ:ALKS) affirms FY2026 sales outlook from $1.730 billion-$1.840 billion to $1.730 bil
Alkermes (NASDAQ:ALKS) reported quarterly sales of $496.009 million which beat the analyst consensus
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarte
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings bea
Stifel analyst Paul Matteis reiterates Alkermes (NASDAQ:ALKS) with a Buy and raises the price tar
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast present
Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target
Alkermes reports positive long-term data for alixorexton, showing sustained wakefulness and symptom
Alkermes plc (NASDAQ:ALKS) today announced results from a planned interim analysis of the ongoing lo
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced results from a planned interim
On July 6, 2026, Alkermes plc (the "Company") and Amneal Pharmaceuticals LLC ("Amneal
Mizuho analyst Uy Ear maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price tar
Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and raise
Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrad
B of A Securities analyst Jason Gerberry downgrades Alkermes (NASDAQ:ALKS) from Neutral to Underp
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs
Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target
On June 23, 2026, Alkermes PLC (ALKS) shares rose 4.3% today, bringing the current price to $48.06.
TD Cowen analyst Joseph Thome maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price ta
Alkermes plc maintains a Buy rating, driven by the accretive Avadel Pharmaceuticals acquisition and
Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax t
Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target
— First Large Phase 2 Study of an Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and
Company seeks to advance national expansion through innovative financing model; Founder personally i
Alkermes plc (NASDAQ:ALKS) today announced that alixorexton, a novel, investigational, oral, selecti
RBC Capital analyst Leonid Timashev maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises
— 26 Abstracts Accepted Demonstrate Alkermes' Commitment to Advancing Understanding and Treatmen
Baird analyst Joel Beatty maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price
Alkermes shares climbed after phase 3 LUMRYZ data met key endpoints in idiopathic hypersomnia as ana
Alkermes plc (NASDAQ:ALKS) today announced positive topline results from the REVITALYZ℠ double-blind
UBS analyst Ashwani Verma maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target
Alkermes reports positive Q1 results, beating expectations. Raises EPS guidance and maintains sales
Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and raise